Clinical Trial Update: A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy [Phase 2]

View source ↗

Summary

Phase II trial evaluating sacituzumab tirumotecan in combination with furmonertinib for non-squamous non-small cell lung cancer that progressed after EGFR-TKI a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Status: RECRUITING